﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Journal of Research in Clinical Medicine</JournalTitle>
      <Issn>2717-0616</Issn>
      <Volume>3</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2015</Year>
        <Month>08</Month>
        <DAY>20</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Hepatic venous outflow block in a young patient with Systemic Lupus Erythematosus</ArticleTitle>
    <FirstPage>190</FirstPage>
    <LastPage>193</LastPage>
    <ELocationID EIdType="doi">10.15171/jarcm.2015.030</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Ali</FirstName>
        <LastName>Ghavidel</LastName>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.15171/jarcm.2015.030</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2014</Year>
        <Month>02</Month>
        <Day>01</Day>
      </PubDate>
    </History>
    <Abstract>Introduction: Hepatic venous outflow block or Budd-Chiari syndrome is a severe liver disease with a 3 years survival rate of 50%. Several conditions have been implicated as a cause of Budd-Chiari syndrome, including myeloproliferative disorders, paroxysmal nocturnal hemoglobinuria, the presence of lupus anti-coagulant, oral contraceptives, pregnancy, and others. In a small number of cases, Budd-Chiari syndrome is associated with the presence of lupus anticoagulant. Anticardiolipin antibodies (ACA) are similar to lupus anti-coagulant antiphospholipid antibodies (APLAs), which have been described in patients with recurrent arterial and venous thrombosis, thrombocytopenia, fetal loss, or miscarriage. Case Report: A 23-year-old woman is reported with Budd-Chiari syndrome in whom lupus anticoagulant and anticardiolipin antibodies were shown; 9 months after diagnosis of systemic lupus erythematosus (SLE) treatment with steroids admitted with gastrointestinal problems, abdominal pain and ascites and treated oral anticoagulants induced a considerable improvement. This treatment was continued after 1 year, but interruption was followed by redevelopment of ascites. Further treatment with anticoagulants was continued for 5 years with noticeable improvement. Conclusion: Patients with Budd-Chiari syndrome should be tested for lupus anticoagulants and anticardiolipin antibodies, Budd-Chiari syndrome resulting from this cause may have a good response to treatment with oral anticoagulants; this treatment should be maintained permanently, and pregnancy in such patients may initiate serious difficulties. The condition of the patient at follow-up was good.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Systemic Lupus Erythematosus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Budd-Chiari Syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nephrotic Syndrome</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>